Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

NCT03072238 PHASE3 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE3
Status	COMPLETED
Enrolment	1101
Start date	Fri Jun 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Apr 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Metastatic Prostate Cancer

Interventions

• Ipatasertib
• Abiraterone
• Placebo
• Prednisone/Prednisolone

Countries

Italy, Japan, Taiwan, Ireland, Poland, South Korea, Denmark, Costa Rica, Russia, Belgium, Mexico, Thailand, Portugal, United States, France, Greece, Austria, Israel, Hungary, Norway, Canada, Brazil, Spain, United Kingdom, Australia, China